Ichnos Glenmark Innovation has announced the development of ISB 2301, a first-in-class multispecific immune cell activator designed for the treatment of multiple solid tumor indications, marking a significant advancement in next-generation cancer immunotherapy research. The new investigational candidate has been engineered to target three tumor-associated antigens simultaneously while activating both T cells and natural killer (NK) cells to trigger a coordinated immune response against cancer cells. The company believes the molecule’s multi-mechanistic approach could address some of the biological complexities that have historically limited the effectiveness of conventional immunotherapies in solid tumors.
According to IGI, ISB 2301 has demonstrated strong preclinical performance, including potent antibody-dependent cellular cytotoxicity, effective checkpoint inhibition and the ability to generate a sustained type 1 immune response. The therapy was developed using the company’s proprietary BEAT® technology platform, which enables the creation and scalable manufacturing of highly complex multispecific antibody structures.
Lida Pacaud, President and Chief Executive Officer of Ichnos Glenmark Innovation, said the company designed ISB 2301 specifically to address the complexity and heterogeneity of solid tumors through simultaneous targeting and dual immune-cell engagement. She stated that the candidate reflects a new level of precision engineering in multispecific antibody development and could potentially establish a new benchmark for immunotherapy approaches in oncology.
Preclinical studies conducted in non-human primates demonstrated favorable pharmacokinetics, strong tolerability and an encouraging safety profile, supporting further development of the therapy. The company plans to submit an Investigational New Drug application by the end of the year and expects to initiate clinical trials in 2027.
IGI also highlighted the growing validation of its multispecific antibody platform following earlier clinical progress achieved with ISB 2001, which led to a strategic collaboration with AbbVie. Company executives noted that the same technology and engineering capabilities behind ISB 2001 enabled the successful design and development of ISB 2301.
Headquartered in New York, IGI is a fully integrated clinical-stage biotechnology company focused on developing innovative biologics for oncology applications. The company’s pipeline includes multiple first-in-class multispecific antibody candidates aimed at treating hematological malignancies and solid tumors through advanced immune-system targeting strategies.
